Literature DB >> 4026919

[Properties and efficacy of a human immunoglobulin M preparation for intravenous administration].

W Stephan, H Dichtelmüller, I Schedel.   

Abstract

From Cohn fraction III a new immunoglobulin (Ig) preparation (Pentaglobin) was prepared. This preparation contains 72% IgG and is enriched in IgM (12%) and IgA (16%). Due to a treatment with beta-propiolactone it is suitable for intravenous application. This IgM-enriched immunoglobulin preparation is prominent in high antibody titers (passive hemagglutination) against gram-negative as well as gram-positive germs and shows significantly higher efficacy in mouse protection tests than intravenous standard IgG. The high IgM content of this preparation in particular is responsible for the binding of bacterial antigens. Thus a marked advancement in the treatment of bacterial infections is to be expected by this new intravenously tolerable immunoglobulin preparation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4026919

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

1.  Re: Prophylaxis of gram-negative and gram-positive infections in rodents with three intravenous immunoglobulins and therapy of experimental polymicrobial burn wound sepsis with pseudomonas immunoglobulin and ciprofloxacin.

Authors:  W Stephan; H Dichtelmüller
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

2.  New aspects in the treatment of gram-negative bacteraemia and septic shock.

Authors:  I Schedel
Journal:  Infection       Date:  1988       Impact factor: 3.553

3.  [Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].

Authors:  M S Collins; R F Hector; R E Roby; A A Edwards; D K Ladehoff; J H Dorsey
Journal:  Infection       Date:  1987       Impact factor: 3.553

4.  Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis.

Authors:  M Mohr; L Englisch; A Roth; H Burchardi; S Zielmann
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

5.  Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins.

Authors:  G Behre; I Schedel; B Nentwig; B Wörmann; M Essink; W Hiddemann
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

6.  [Prevention of gram-negative and gram-positive infections using 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection using intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].

Authors:  M S Collins; R F Hector; R E Roby; A A Edwards; D K Ladehoff; J H Dorsey
Journal:  Infection       Date:  1987 Jan-Feb       Impact factor: 3.553

Review 7.  Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections.

Authors:  Jeroen D Langereis; Michiel van der Flier; Marien I de Jonge
Journal:  Front Immunol       Date:  2018-08-23       Impact factor: 7.561

Review 8.  Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Authors:  Kang Cai; Todd M Gierman; JoAnn Hotta; Christopher J Stenland; Douglas C Lee; Dominique Y Pifat; Steve R Petteway
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.